Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

By P. Prorok, G. Andriole, R. Bresalier, S. Buys, D. Chia, E. Crawford, R. Fogel, E. Gelmann, F. Gilbert, M. Hasson and 12 more. Controlled Clinical Trials, 2000

1,022 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/913cd58807990b0de85b18dc2961d41363076611

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Edward L. Giovannucci
2. Mahesh K B Parmar
3. M. Thun
4. E. Calle
5. W. Willett

Citations in the corpus

• Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. (2007, background): “The original power calculations for PLCO did assume some magnitude of a healthy volunteer effect, and thus the results reported here do not imply that the power of the PLCO is compromised (6).”
• Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 (2007, methodology): “We conducted a genome-wide association study (GWAS) of 550,000 SNPs in 1,172 affected individuals (484 with nonaggressive prostate cancer, Gleason”
• Multiple loci identified in a genome-wide association study of prostate cancer (2008, methodology): “We conducted the initial genome-wide scan in a nested case-control study of 1,172 prostate-specific antigen (PSA) screened cases (oversampled for aggressive cases; 484 nonaggressive prostate cancer (Gleason score”
• Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials (2011, background): “health care organization lists which were not generally population based [ 11 ].”